Although accumulating evidence highlights FGF21’s immense therapeutic potential for metabolic disorders such as obesity, insulin resistance, and type 2 diabetes, key gaps persist in our understanding of its systemic actions. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.